Another 22 drugs were called out "dual-channel", and the classification of 49 countries has changed.

　　On August 23, the Jiangxi Provincial Medical Insurance Bureau issued the "Announcement on the Dynamic Adjustment of the Classification and Management of Some National Medical Insurance Negotiated Drugs in Our Province".
In accordance with the principles of Jiangxi Province's negotiated drug classification management, combined with the application of some enterprises, it is proposed to "Maggi Company".
49 national medical insurance negotiation drug classification management categories such as "He Capsule" will be dynamically adjusted (see the attached table at the end of the article for the specific list)
.
From the content of the announcement, 19 drugs were adjusted from Class B to Class A, 22 drugs were adjusted from Class B to Class C, 2 drugs were adjusted from Class C to Class A, and 6 drugs were adjusted from Class C to Class B
.
According to the previous classification regulations, this also means that there are 22 countries talking about the "dual-channel" management of drugs
.
Previously, on March 14, 2022, the Jiangxi Provincial Medical Insurance Bureau and other four departments jointly issued the "Notice on Further Implementing the Implementation of National Medical Insurance Negotiated Drugs", which clearly comprehensively considers clinical value, patients' needs for rational drug use, course cost burden, substitution Negotiated drugs are divided into three categories for management based on factors such as sex, affordability of medical insurance funds,
etc.
Negotiated drugs with a long use cycle and high treatment course cost are included in the "dual-channel" category A drug management; drugs with high clinical value, urgent needs of patients, low substitution, specific drug users (serious diseases or emergency needs of infectious diseases, etc.
) Negotiated drugs are included in the "dual-channel" category B drug management; negotiated drugs that cannot or should not be sold in pharmacies due to the policy regulations of the industry competent authorities, or are easily abused and easily lead to uncontrollable medical insurance fund expenditures are managed as category C, and are not included in the "dual-channel" category.
"Management Scope
.
The "Notice" clarifies that when the insured people use Class A and Class B negotiated drugs in hospital or outpatient clinics, they are included in the scope of the overall fund payment, and the current treatment policies are consistent
.
For Class A and Class B negotiated drugs that are temporarily unavailable to dual-channel medical institutions, the prescriptions issued by the responsible physicians can be transferred to dual-channel pharmacies through the prescription circulation platform of the medical security department to effectively improve the availability of negotiated drugs
.
In addition, the annual accumulated drug expenses of the insured people using negotiated drugs shall be calculated in combination with the maximum payment limit of basic medical insurance and serious illness insurance funds.

.
Class A drugs are paid in a separate line, with no threshold and personal payment ratio, and are paid according to the highest payment standard of medical insurance and the fixed fee policy borne by individuals
.
For Class B drugs, there is no minimum payment line, and the individual pays 10% first, and then pays according to the highest payment standard of medical insurance and the fixed fee policy borne by the individual
.
The personal burden of the negotiated drugs can also be included in the serious illness insurance and medical assistance fund payment according to regulations
.
In fact, Jiangxi has already had a number of "dual-channel" management of nationally-discussed varieties
.
On January 6, 2022, Iloyoumab injection will be transferred out of the "dual-channel" drug list, and will be managed as a class B drug negotiated by the national medical insurance
.
On March 18, Jiangxi Provincial Medical Insurance Bureau transferred sodium zirconium cyclosilicate powder to the list of "dual-channel" drugs, and managed it according to the national medical insurance negotiation drug category
B.
On June 1, 2022, the Jiangxi Provincial Medical Insurance Bureau issued the "Notice on Transferring 19 Drugs including "Bailing Capsule" from the Dual-Channel Drug List
.
"Bailing Capsules", "Acarbose Chewable Tablets", "Metformin Empagliflozin Tablets (Ⅰ)", "Dulaglutide Injection", "Lanqin Oral Liquid", "Chaiqin Qingning Capsules", "Shenwu Yishen Tablets" ""Glycyrrhizin Monoammonium Cysteine ​​Sodium Chloride Injection", "Tanshinone IIA Sodium Sulfonate Injection", "Tipefilgrastim Injection", "Paclitaxel Liposome for Injection", "Bone Pain Relief Gel"" Capsules for Indacaterogronium Bromide Inhalation Powder Inhalation Powder (Indacaterogronium Bromide Inhalation Powder Spray)", "Levosalbutamol Hydrochloride Nebulized Inhalation Solution", "Niuhuang Qinggan Capsule", "Honeysuckle Oral Liquid"" Liraglutide Injection, Benaglutide Injection and Compound Amino Acid Injection (18AA-V-SF) have called out the list of dual-channel drugs in our province, and are managed according to the national medical insurance negotiation drug category
B.
According to Jiangxi Province's public notice, the withdrawal of these varieties from the dual-channel list is the independent application of drug manufacturers
.
As of June 1 this year, a total of 38 drugs in Jiangxi have voluntarily applied for withdrawal
.
Judging from the current withdrawal of dual-channel drugs, most of them are category
B.
Although different regions have different regulations on specific national drugs in terms of dual-channel policies, some national drugs are temporarily unable to enter dual channels
.
Many pharmaceutical companies are still willing to open up in-hospital sales through the dual-channel route, and Jiangxi has never voluntarily applied for withdrawal
.
According to the "Health Knowledge Bureau", some companies reported that some products that entered the dual channel could not be reimbursed
.
According to the regulations of the National Medical Insurance Bureau, "dual-channel" drugs are simultaneously included in medical insurance payment, and the reimbursement policies in designated hospitals and designated retail pharmacies
are the same .
However, in the specific implementation in Jiangxi, there have been cases where patients cannot purchase medical insurance for some "dual-channel" drugs
.
As a result, there has been a situation in which the company withdraws voluntarily
.
However, some provinces have also issued documents to make dynamic adjustments to the medical insurance "dual-channel" drug
management catalogue, such as Jiangsu and Xinjiang .
We have also compiled some policies on the implementation of dual-channel medical insurance for reference
.
"Tianfeng Securities" pointed out in a research report that dual channels are expected to usher in the accelerated volume of innovative drugs, bringing more possibilities to patients; innovative drug leaders and chain pharmacy leaders are expected to usher in new increments
.
At the same time, a significant impact of the dual-channel policy is to promote the outflow of prescriptions.
With the support of the policy, Guotan drugs should be able to make a difference on the prescription circulation platform
.
However, in the actual operation process, the circulation of prescriptions is really not as easy as imagined! Standard Corporate Hospital Pharmacy Drugs